1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Acquired Gene or Chromosome Alterations - Pipeline Review, 2015

Acquired Gene or Chromosome Alterations - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Acquired Gene or Chromosome Alterations - Pipeline Review, 2015" provides an overview of genetic tests for Acquired Gene or Chromosome Alterations currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key genetic tests for Acquired Gene or Chromosome Alterations pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the genetic tests for Acquired Gene or Chromosome Alterations under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of genetic tests for Acquired Gene or Chromosome Alterations and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of genetic tests for Acquired Gene or Chromosome Alterations under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Acquired Gene or Chromosome Alterations - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 17
2 Introduction 18
2.1 Acquired Gene or Chromosome Alterations Overview 18
3 Products under Development 19
3.1 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 19
3.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Territory 20
3.3 Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 21
3.4 Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 22
4 Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies 23
4.1 Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 23
4.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 26
5 Acquired Gene or Chromosome Alterations Companies and Product Overview 36
5.1 Abbott Diagnostics Company Overview 36
5.1.1 Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 36
5.2 Agendia NV Company Overview 177
5.2.1 Agendia NV Pipeline Products and Ongoing Clinical Trials Overview 177
5.3 AltheaDx, Inc. Company Overview 178
5.3.1 AltheaDx, Inc. Pipeline Products and Ongoing Clinical Trials Overview 178
5.4 Amarantus Bioscience Holdings, Inc. Company Overview 181
5.4.1 Amarantus Bioscience Holdings, Inc. Pipeline Products and Ongoing Clinical Trials Overview 181
5.5 AstraZeneca Plc Company Overview 183
5.5.1 AstraZeneca Plc Pipeline Products and Ongoing Clinical Trials Overview 183
5.6 AutoGenomics, Inc. Company Overview 185
5.6.1 AutoGenomics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 185
5.7 Biocept, Inc. Company Overview 186
5.7.1 Biocept, Inc. Pipeline Products and Ongoing Clinical Trials Overview 186
5.8 Cepheid Company Overview 189
5.8.1 Cepheid Pipeline Products and Ongoing Clinical Trials Overview 189
5.9 Chinese University of Hong Kong Company Overview 192
5.9.1 Chinese University of Hong Kong Pipeline Products and Ongoing Clinical Trials Overview 192
5.10 Columbia University Company Overview 194
5.10.1 Columbia University Pipeline Products and Ongoing Clinical Trials Overview 194
5.11 Dana-Farber Cancer Institute, Inc. Company Overview 195
5.11.1 Dana-Farber Cancer Institute, Inc. Pipeline Products and Ongoing Clinical Trials Overview 195
5.12 DiaCarta Company Overview 196
5.12.1 DiaCarta Pipeline Products and Ongoing Clinical Trials Overview 196
5.13 Exosome Diagnostics, Inc. Company Overview 197
5.13.1 Exosome Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 197
5.14 Gencurix Co., Ltd. Company Overview 198
5.14.1 Gencurix Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 198
5.15 GeneFirst Ltd Company Overview 199
5.15.1 GeneFirst Ltd Pipeline Products and Ongoing Clinical Trials Overview 199
5.16 GenMark Diagnostics, Inc. Company Overview 203
5.16.1 GenMark Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 203
5.17 Genomic Health, Inc. Company Overview 205
5.17.1 Genomic Health, Inc. Pipeline Products and Ongoing Clinical Trials Overview 205
5.18 Genomic Vision Company Overview 207
5.18.1 Genomic Vision Pipeline Products and Ongoing Clinical Trials Overview 207
5.19 GenomicTree, Inc. Company Overview 210
5.19.1 GenomicTree, Inc. Pipeline Products and Ongoing Clinical Trials Overview 210
5.20 German Cancer Research Center Company Overview 212
5.20.1 German Cancer Research Center Pipeline Products and Ongoing Clinical Trials Overview 212
5.21 H. Lee Moffitt Cancer Center and Research Institute, Inc. Company Overview 214
5.21.1 H. Lee Moffitt Cancer Center and Research Institute, Inc. Pipeline Products and Ongoing Clinical Trials Overview 214
5.22 Harvard University Company Overview 216
5.22.1 Harvard University Pipeline Products and Ongoing Clinical Trials Overview 216
5.23 Helmholtz Centre for Infection Research Company Overview 217
5.23.1 Helmholtz Centre for Infection Research Pipeline Products and Ongoing Clinical Trials Overview 217
5.24 HistoRx, Inc. (Inactive) Company Overview 218
5.24.1 HistoRx, Inc. (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 218
5.25 Illumina, Inc. Company Overview 220
5.25.1 Illumina, Inc. Pipeline Products and Ongoing Clinical Trials Overview 220
5.26 Insight Genetics, Inc. Company Overview 223
5.26.1 Insight Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 223
5.27 InVivoScribe Technologies, Inc. Company Overview 225
5.27.1 InVivoScribe Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 225
5.28 Med BioGene Inc. Company Overview 226
5.28.1 Med BioGene Inc. Pipeline Products and Ongoing Clinical Trials Overview 226
5.29 Merrimack Pharmaceuticals, Inc. Company Overview 227
5.29.1 Merrimack Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 227
5.30 MolecularMD, Corp. Company Overview 229
5.30.1 MolecularMD, Corp. Pipeline Products and Ongoing Clinical Trials Overview 229
5.31 Multiplicom N.V. Company Overview 230
5.31.1 Multiplicom N.V. Pipeline Products and Ongoing Clinical Trials Overview 230
5.32 Myriad Genetics, Inc. Company Overview 231
5.32.1 Myriad Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 231
5.33 Nanosphere, Inc. Company Overview 234
5.33.1 Nanosphere, Inc. Pipeline Products and Ongoing Clinical Trials Overview 234
5.34 New York University Company Overview 237
5.34.1 New York University Pipeline Products and Ongoing Clinical Trials Overview 237
5.35 NIH Office of Technology Transfer Company Overview 238
5.35.1 NIH Office of Technology Transfer Pipeline Products and Ongoing Clinical Trials Overview 238
5.36 Oryzon Genomics S.A. Company Overview 240
5.36.1 Oryzon Genomics S.A. Pipeline Products and Ongoing Clinical Trials Overview 240
5.37 Oxford Biodynamics Limited Company Overview 241
5.37.1 Oxford Biodynamics Limited Pipeline Products and Ongoing Clinical Trials Overview 241
5.38 Panagene Inc. Company Overview 246
5.38.1 Panagene Inc. Pipeline Products and Ongoing Clinical Trials Overview 246
5.39 Pangaea Biotech, S.L. Company Overview 250
5.39.1 Pangaea Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 250
5.40 PDI, lnc. Company Overview 254
5.40.1 PDI, lnc. Pipeline Products and Ongoing Clinical Trials Overview 254
5.41 PharmaSeq, Inc. Company Overview 256
5.41.1 PharmaSeq, Inc. Pipeline Products and Ongoing Clinical Trials Overview 256
5.42 Qiagen N.V. Company Overview 258
5.42.1 Qiagen N.V. Pipeline Products and Ongoing Clinical Trials Overview 258
5.43 RedPath Integrated Pathology, Inc. Company Overview 268
5.43.1 RedPath Integrated Pathology, Inc. Pipeline Products and Ongoing Clinical Trials Overview 268
5.44 Response Genetics, Inc. Company Overview 269
5.44.1 Response Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 269
5.45 Rheonix, Inc. Company Overview 272
5.45.1 Rheonix, Inc. Pipeline Products and Ongoing Clinical Trials Overview 272
5.46 Seegene, Inc. Company Overview 274
5.46.1 Seegene, Inc. Pipeline Products and Ongoing Clinical Trials Overview 274
5.47 Shuwen Biotech Co. Ltd. Company Overview 276
5.47.1 Shuwen Biotech Co. Ltd. Pipeline Products and Ongoing Clinical Trials Overview 276
5.48 Syamala Srinivasa Life Sciences Pvt. Ltd Company Overview 284
5.48.1 Syamala Srinivasa Life Sciences Pvt. Ltd Pipeline Products and Ongoing Clinical Trials Overview 284
5.49 Sygnis AG Company Overview 288
5.49.1 Sygnis AG Pipeline Products and Ongoing Clinical Trials Overview 288
5.50 Sysmex Corporation Company Overview 290
5.50.1 Sysmex Corporation Pipeline Products and Ongoing Clinical Trials Overview 290
5.51 The Johns Hopkins University Company Overview 292
5.51.1 The Johns Hopkins University Pipeline Products and Ongoing Clinical Trials Overview 292
5.52 thromboDx Company Overview 294
5.52.1 thromboDx Pipeline Products and Ongoing Clinical Trials Overview 294
5.53 Transbiomed, SL Company Overview 296
5.53.1 Transbiomed, SL Pipeline Products and Ongoing Clinical Trials Overview 296
5.54 Transgenomic, Inc. Company Overview 297
5.54.1 Transgenomic, Inc. Pipeline Products and Ongoing Clinical Trials Overview 297
5.55 TrovaGene, Inc. Company Overview 299
5.55.1 TrovaGene, Inc. Pipeline Products and Ongoing Clinical Trials Overview 299
5.56 University of California, Irvine Company Overview 301
5.56.1 University of California, Irvine Pipeline Products and Ongoing Clinical Trials Overview 301
5.57 Vela Diagnostics Company Overview 302
5.57.1 Vela Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 302
5.58 Xiamen Zeesan Biotech Co.,Ltd Company Overview 307
5.58.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 307
6 Acquired Gene or Chromosome Alterations- Recent Developments 311
7 Appendix 345
7.1 Methodology 345
7.2 About GlobalData 347
7.3 Contact Us 348
7.4 Disclaimer 348

1.1 List of Tables
Table 1: Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 19
Table 2: Acquired Gene or Chromosome Alterations - Pipeline Products by Territory 20
Table 3: Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 21
Table 4: Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 22
Table 5: Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development 23
Table 6: Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 26
Table 7: Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 36
Table 8: 13q14.3 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status 42
Table 9: 13q14.3 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description 42
Table 10: AKT Companion Diagnostic Assay - Renal Cancer - Product Status 43
Table 11: AKT Companion Diagnostic Assay - Renal Cancer - Product Description 43
Table 12: ALK Companion Diagnostic Assay - Colorectal Cancer - Product Status 44
Table 13: ALK Companion Diagnostic Assay - Colorectal Cancer - Product Description 44
Table 14: AR Companion Diagnostic Assay - Prostate Cancer - Product Status 45
Table 15: AR Companion Diagnostic Assay - Prostate Cancer - Product Description 45
Table 16: ATM Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status 46
Table 17: ATM Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description 46
Table 18: AURKA Companion Diagnostic Assay - Prostate Cancer - Product Status 47
Table 19: AURKA Companion Diagnostic Assay - Prostate Cancer - Product Description 47
Table 20: AXL Companion Diagnostic Assay - Lung Cancer - Product Status 48
Table 21: AXL Companion Diagnostic Assay - Lung Cancer - Product Description 48
Table 22: BCL2 Companion Diagnostic Assay - Leukemia - Product Status 49
Table 23: BCL2 Companion Diagnostic Assay - Leukemia - Product Description 49
Table 24: BCL2 Companion Diagnostic Assay - Lymphoma - Product Status 50
Table 25: BCL2 Companion Diagnostic Assay - Lymphoma - Product Description 50
Table 26: BCL6 Companion Diagnostic Assay - Lymphoma - Product Status 51
Table 27: BCL6 Companion Diagnostic Assay - Lymphoma - Product Description 51
Table 28: BRAF Companion Diagnostic Assay - Colon Cancer - Product Status 52
Table 29: BRAF Companion Diagnostic Assay - Colon Cancer - Product Description 52
Table 30: BRAF Companion Diagnostic Assay - Gastric Cancer - Product Status 53
Table 31: BRAF Companion Diagnostic Assay - Gastric Cancer - Product Description 53
Table 32: BRAF Companion Diagnostic Assay - Glioblastoma - Product Status 54
Table 33: BRAF Companion Diagnostic Assay - Glioblastoma - Product Description 54
Table 34: BRAF Companion Diagnostic Assay - Lung Cancer - Product Status 55
Table 35: BRAF Companion Diagnostic Assay - Lung Cancer - Product Description 55
Table 36: BRAF Companion Diagnostic Assay - Melanoma - Product Status 56
Table 37: BRAF Companion Diagnostic Assay - Melanoma - Product Description 56
Table 38: BRAF Companion Diagnostic Assay - Ovarian Cancer - Product Status 57
Table 39: BRAF Companion Diagnostic Assay - Ovarian Cancer - Product Description 57
Table 40: BRCA1 Companion Diagnostic Assay - Ovarian Cancer - Product Status 58
Table 41: BRCA1 Companion Diagnostic Assay - Ovarian Cancer - Product Description 58
Table 42: BRCA2 Companion Diagnostic Assay - Ovarian Cancer - Product Status 59
Table 43: BRCA2 Companion Diagnostic Assay - Ovarian Cancer - Product Description 59
Table 44: CCND1 Companion Diagnostic Assay - Lymphoma - Product Status 60
Table 45: CCND1 Companion Diagnostic Assay - Lymphoma - Product Description 60
Table 46: CDKN2A Companion Diagnostic Assay - Bladder Cancer - Product Status 61
Table 47: CDKN2A Companion Diagnostic Assay - Bladder Cancer - Product Description 61
Table 48: CDKN2C Companion Diagnostic Assay - Multiple Myeloma - Product Status 62
Table 49: CDKN2C Companion Diagnostic Assay - Multiple Myeloma - Product Description 62
Table 50: Chromosome 12 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status 63
Table 51: Chromosome 12 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description 63
Table 52: Chromosome 17 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status 64
Table 53: Chromosome 17 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description 64
Table 54: Chromosome 4 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status 65
Table 55: Chromosome 4 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description 65
Table 56: Chromosome 7 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status 66
Table 57: Chromosome 7 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description 66
Table 58: Chromosome 7 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status 67
Table 59: Chromosome 7 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description 67
Table 60: Chromosome 8 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status 68
Table 61: Chromosome 8 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description 68
Table 62: Chromosome X Companion Diagnostic Assay - Cervical Cancer - Product Status 69
Table 63: Chromosome X Companion Diagnostic Assay - Cervical Cancer - Product Description 69
Table 64: CKS1B Companion Diagnostic Assay - Multiple Myeloma - Product Status 70
Table 65: CKS1B Companion Diagnostic Assay - Multiple Myeloma - Product Description 70
Table 66: COT Companion Diagnostic Assay - Melanoma - Product Status 71
Table 67: COT Companion Diagnostic Assay - Melanoma - Product Description 71
Table 68: CRAF Companion Diagnostic Assay - Melanoma - Product Status 72
Table 69: CRAF Companion Diagnostic Assay - Melanoma - Product Description 72
Table 70: D5S721 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status 73
Table 71: D5S721 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description 73
Table 72: D7S486 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status 74
Table 73: D7S486 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description 74
Table 74: D7S552 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Status 75
Table 75: D7S552 Companion Diagnostic Assay - Acute Myeloid Leukemia - Product Description 75
Table 76: DCC Companion Diagnostic Assay - Colorectal Cancer - Product Status 76
Table 77: DCC Companion Diagnostic Assay - Colorectal Cancer - Product Description 76
Table 78: DDR2 Companion Diagnostic Assay - Lung Cancer - Product Status 77
Table 79: DDR2 Companion Diagnostic Assay - Lung Cancer - Product Description 77
Table 80: del(13q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status 78
Table 81: del(13q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description 78
Table 82: del(17p) Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status 79
Table 83: del(17p) Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description 79
Table 84: del(17p) Companion Diagnostic Assay - Multiple Myeloma - Product Status 80
Table 85: del(17p) Companion Diagnostic Assay - Multiple Myeloma - Product Description 80
Table 86: del(5q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status 81
Table 87: del(5q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description 81
Table 88: del(7q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status 82
Table 89: del(7q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description 82
Table 90: del(9q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Status 83
Table 91: del(9q) Companion Diagnostic Assay - Myelodysplastic Syndrome - Product Description 83
Table 92: EGFR Companion Diagnostic Assay - Brain Cancer - Product Status 84
Table 93: EGFR Companion Diagnostic Assay - Brain Cancer - Product Description 84
Table 94: EGFR Companion Diagnostic Assay - Glioblastoma - Product Status 85
Table 95: EGFR Companion Diagnostic Assay - Glioblastoma - Product Description 85
Table 96: EGFR Companion Diagnostic Assay - Lung Cancer - Product Status 86
Table 97: EGFR Companion Diagnostic Assay - Lung Cancer - Product Description 86
Table 98: EGFRvIII Companion Diagnostic Assay - Glioblastoma - Product Status 87
Table 99: EGFRvIII Companion Diagnostic Assay - Glioblastoma - Product Description 87
Table 100: EGFRvIII Companion Diagnostic Assay - Lung Cancer - Product Status 88
Table 101: EGFRvIII Companion Diagnostic Assay - Lung Cancer - Product Description 88
Table 102: ERBB3 Companion Diagnostic Assay - Bladder Cancer - Product Status 89
Table 103: ERBB3 Companion Diagnostic Assay - Bladder Cancer - Product Description 89
Table 104: ETV Companion Diagnostic Assay - Sarcoma - Product Status 90
Table 105: ETV Companion Diagnostic Assay - Sarcoma - Product Description 90
Table 106: FGFR1 Companion Diagnostic Assay - Prostate Cancer - Product Status 91
Table 107: FGFR1 Companion Diagnostic Assay - Prostate Cancer - Product Description 91
Table 108: FGFR2 Companion Diagnostic Assay - Colorectal Cancer - Product Status 92
Table 109: FGFR2 Companion Diagnostic Assay - Colorectal Cancer - Product Description 92
Table 110: FGFR2 Companion Diagnostic Assay - Gastric Cancer - Product Status 93
Table 111: FGFR2 Companion Diagnostic Assay - Gastric Cancer - Product Description 93
Table 112: FGFR2 Companion Diagnostic Assay - Lung Cancer - Product Status 94
Table 113: FGFR2 Companion Diagnostic Assay - Lung Cancer - Product Description 94
Table 114: FGFR3 Companion Diagnostic Assay - Bladder Cancer - Product Status 95
Table 115: FGFR3 Companion Diagnostic Assay - Bladder Cancer - Product Description 95
Table 116: FGFR3-TACC3 Companion Diagnostic Assay - Lung Cancer - Product Status 96
Table 117: FGFR3-TACC3 Companion Diagnostic Assay - Lung Cancer - Product Description 96
Table 118: GNA11 Companion Diagnostic Assay - Melanoma - Product Status 97
Table 119: GNA11 Companion Diagnostic Assay - Melanoma - Product Description 97
Table 120: GNAQ Companion Diagnostic Assay - Melanoma - Product Status 98
Table 121: GNAQ Companion Diagnostic Assay - Melanoma - Product Description 98

1.2 List of Figures
Figure 1: Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development 19
Figure 2: Acquired Gene or Chromosome Alterations - Pipeline Products by Territory 20
Figure 3: Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path 21
Figure 4: Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date 22

Companies Mentioned
Abbott Diagnostics
Agendia NV
AltheaDx, Inc.
Amarantus Bioscience Holdings, Inc.
AstraZeneca Plc
AutoGenomics, Inc.
Biocept, Inc.
Cepheid
Chinese University of Hong Kong
Columbia University
Dana-Farber Cancer Institute, Inc.
DiaCarta
Exosome Diagnostics,

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Pollution Control Statistics in the US

  • November 2016
    218 pages
  • Pollution Contr...  

    Cancer  

    Metals  

  • United States  

    North America  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.